Value Creation

A Disciplined, Hands‑on Approach

Empty glass vials move along a conveyor with black rollers on an automated pharmaceutical packaging line.

1315 Capital’s Value Creation Approach

We create value through hands-on partnership. From diligence to exit, we align with management on clear priorities, provide operating support where it matters most, and help position healthcare companies for sustainable growth.

Rows of glass vaccine vials with blue caps move along an automated filling line under stainless-steel nozzles in a sterile pharma facility.
Automated lab analyzer processing test tubes filled with yellow samples.

Investment Leadership

1315 Capital partners are lifelong investors in growth-stage healthcare, with a track record of success through multiple market cycles.

The investment partners marry expertise in commercial and investment banking with healthcare company operating experience, providing critical perspectives when evaluating and managing healthcare growth investments.

Scientist in cleanroom PPE analyzing data on dual monitors at a lab workstation.

Operating Teams

1315 Capital leverages an operating team model of healthcare industry executives who help provide a more complete perspective to navigate diligence, drive decisions, and achieve premium exits.

The operating team members remain active within the healthcare industry, allowing 1315 Capital to benefit from “on the ground” perspectives in the market. These individuals have built companies from expansion and growth phases to entities with revenues in excess of $100 million and have contributed to the creation of billions of aggregate shareholder value.

Macro shot of microscope objective lenses focusing on an illuminated slide, with gloved hands adjusting.

Tangible Engagement

We believe that fast-growing companies can leverage 1315 Capital’s deep experience, extensive networks, and resources to successfully navigate dynamic and evolving environments.

We believe it is critical to take ownership of our portfolio companies’ success in partnership with management. Our networks, operating teams, and advisors are all sourced with the intent of supporting existing management, improving execution, and ultimately creating ideal environments for exit.

Portfolio

Companies Built for Growth

Specialty manufacturer of hydrophilic coatings used in medical devices.

1315 Capital was more than an investor — they were true partners. Their financial support, strategic insight, and support of our vision enabled Biocoat to grow from a small specialty player into a market leading hydrophilic coating company for medical devices in the U.S. in under four years. Together, we achieved a transformational outcome.

Jim Moran

CEO of Biocoat

Learn More

Leading medical equipment liquidation and resale platform, specializing in auctions and facility liquidations.

I founded Centurion Service Group in 2001 and had built it into the country’s largest medical equipment auction house. I had many investors interested in the business but ultimately chose 1315 Capital due to their healthcare expertise and their buy-in to my vision for the business. Through 1315 Capital’s investment, I was able to generate significant liquidity through a majority recapitalization and I retained a meaningful rollover stake in the business as well as staying on as CEO.

Erik Tivin

CEO of Centurion Service Group

Learn More

Innovator in surgical orthopedic oncology solutions, including limb salvage implants and personalized 3D surgical planning.

1315 Capital’s investment and early strategic involvement were critical to the founding of Onkos Surgical. We successfully carved out assets from a strategic as part of a shared vision of addressing an underserved market in musculoskeletal oncology and complex orthopedics. This approach not only accelerated our entry into the market but also created meaningful long-term value for patients, providers, and investors.

Patrick Treacy

CEO of Onkos Surgical

Learn More

Preclinical contract research organization (CRO) providing end-to-end drug discovery and early development assay services.

1315 Capital quickly got up to speed on the nuances of our business, and the specific opportunities and issues we faced. We had an exceedingly difficult international transaction we were working on to buy out a foreign shareholder that involved months of complex negotiation. 1315 Capital completed the transaction and turned out to be the perfect partner we needed, as we were able to leverage their healthcare industry experience and network to help navigate the company to a successful exit.

Matt Oristano

CEO of Reaction Biology

Learn More

Premium skin health brand offering award-winning sun protection and corrective skincare products.

The 1315 team invested in Colorescience at a pivotal time, leading our Series C round of financing and unlocking substantial growth. Together we refined the unique brand promise of multi-functional, science-backed products tailored for everyday use. Colorescience benefitted from active thought partnership, analytical support, brand advocacy, and access to healthcare networks.

Mary Fisher

CEO of Colorescience

Learn More
Biocoat thermal coating system on an automated manufacturing line inside a cleanroom.
Row of ultrasound machines on wheeled carts displayed in a medical equipment showroom.
Surgical team in protective gowns and masks preparing for a procedure.
Lab technician in gloves pipetting blue samples into test tubes beside a microscope.
Colorescience skincare product lineup—bottles and tubes displayed on blue blocks against a light blue background.
Have an opportunity that fits our focus? Contact us — we’d like to hear from you.